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Abstract
Purpose The CRASH-3 trial is a randomised trial of tranexamic acid (TXA) on death and disability in patients with traumatic 
brain injury (TBI). It is based on the hypothesis that early TXA treatment can prevent deaths from post-traumatic intracranial 
bleeding. The results showed that timely TXA treatment reduces head injury deaths in patients with reactive pupils and those 
with a mild to moderate GCS at baseline. We examined routinely collected CT scans in a sample of 1767 CRASH-3 trial 
patients to explore if, why, and how patients are affected by TXA.
Methods The CRASH-3 IBMS is an explanatory study nested within the CRASH-3 trial. We measured the volume of 
intracranial bleeding on CT scans using established methods (e.g. ABC/2).
Results Patients with any un-reactive pupil had a median intracranial bleeding volume of 60 ml (IQR 18–101 ml) and 
patients with reactive pupils had a median volume of 26 ml (IQR 1–55 ml). Patients with severe GCS had median intracra-
nial bleeding volume of 37 ml (IQR 3–75 ml) and patients with moderate to mild GCS had a median volume of 26 ml (IQR 
0.4–50 ml). For every hour increase from injury to the baseline scan, the risk of new bleeding on a further scan decreased 
by 12% (adjusted RR = 0.88 [95% CI 0.80–0.96], p = 0.0047).
Conclusion Patients with reactive pupils and/or mild to moderate GCS may have benefited from TXA in the CRASH-3 trial 
because they had less intracranial bleeding at baseline. However, because bleeding occurs soon after injury, treatment delay 
reduces the benefit of TXA.
Keywords Traumatic brain injury · Tranexamic acid
Abbreviations
CI  Confidence interval
CRASH-3  Clinical Randomisation of an Antifibrinolytic 
in Significant Head Injury 
CT  Computed tomography
EDH  Epidural haemorrhage
GCS  Glasgow coma score
IBMS  Intracranial bleeding mechanistic study
IPH  Intra-parenchymal haemorrhage
IQR  Interquartile range
IVH  Intra-ventricular haemorrhage
RR  Relative risk
SDH  Subdural haemorrhage
TBI  Traumatic brain injury
Introduction
The CRASH-3 trial is a multi-centre, randomised, placebo-
controlled trial of the effects of tranexamic acid on death and 
disability in patients with traumatic brain injury (TBI) [1]. 
Adults with TBI who were within 3 h of their injury and had 
a Glasgow coma scale score (GCS) ≤ 12 or any intracranial 
bleeding on CT scan were included in the primary analysis. 
We hypothesised that early administration of tranexamic 
acid might prevent deaths from post-traumatic intracranial 
bleeding. We found that rapid tranexamic acid treatment 
reduces head injury deaths in patients with mild to mod-
erate head injury (RR = 0.78 95% CI 0.64–0.95) but there 
was no apparent reduction in severe head injury (RR = 0.99, 
95% CI 0.91–1.07), regardless of time to treatment. Because 
The members of the CRASH-3 Intracranial Bleeding Mechanistic 
Study Collaborators are listed in acknowledgements.
 * The CRASH-3 Intracranial Bleeding Mechanistic Study 
Collaborators
1 Clinical Trials Unit, Faculty of Epidemiology and Population 
Health, London School of Hygiene and Tropical Medicine, 
Keppel Street, London WC1E 7HT, UK
  
1 3
our main aim was to assess the effect of tranexamic acid on 
head injury death, to simplify the trial procedures, we did 
not plan to collect data on the amount of intracranial bleed-
ing in all patients. However, while the trial was underway, 
the data monitoring committee asked us to consider col-
lecting these data on a sample of trial patients “to explore 
if, why, and how patients are affected by tranexamic acid.” 
In response, routinely collected brain imaging data (mainly 
CT scans) were assessed in 1767 CRASH-3 trial patients. 
These patients were scanned before and/or after randomisa-
tion. Because early TXA treatment is expected to be more 
effective than late treatment [2], to reduce time to randomi-
sation, many patients were randomised into the CRASH-3 
trial before CT (i.e. not all 1767 patients in the IBMS had 
their hospital admission scan done before randomisation). 
A total of 1147 patients in the IBMS had a baseline (prior to 
randomisation) CT scan, of whom 812 patients had another 
clinically indicated brain scan. We measured the volume of 
intracranial bleeding on all scans using established methods 
(e.g. ABC/2) [3] and collected data on other CT features of 
TBI. Here we consider the CRASH-3 trial results in light of 
the CT scan data.
The main aim of this paper is to describe the occurrence 
of intracranial pathologies (especially intracranial bleeding) 
at baseline. In patients who are re-scanned after randomisa-
tion into the trial, the data has been collapsed across treat-
ment groups. This is because there are important methodo-
logical flaws when using routinely collected scans to explore 
the effect of tranexamic acid on intracranial bleeding and 
other endpoints measured on post-randomisation imaging. 
Scans may have been done after randomisation because a 
patient did or did not receive tranexamic acid, and so treat-
ment effect estimates are at high risk of bias. This critique 
is beyond the scope of the current paper and so will not be 
presented here.
Methods
Detailed protocols for the CRASH-3 trial and Intracranial 
Bleeding Mechanistic Study (IBMS) are published sepa-
rately [4, 5]. These will be briefly summarised here.
Eligible patients were randomly allocated to receive 
tranexamic acid or matching placebo (0.9% sodium chloride) 
by intravenous infusion. Baseline information was collected 
on the trial entry form. This included an assessment of injury 
severity using the GCS (eye, verbal and motor responses) and 
pupil reaction (both react, one reacts, none react). After the 
trial entry form was complete, the lowest-numbered treat-
ment pack remaining from a box of eight treatment packs was 
taken. If the ampoules inside the treatment pack were intact, 
the patient was considered randomised into the trial. Entry 
form data were entered into a secure online database by the 
trial investigators. Patients and study staff (site investigators 
and trial coordinating centre staff) were masked to allocation. 
Once randomised, outcome data were collected even if the 
treatment was not given (in accord with the intention to treat 
principle). Outcome data were collected 28 days after ran-
domisation, at discharge from the randomising hospital, or at 
death (whichever was first).
The CRASH-3 IBMS is an explanatory study nested within 
the CRASH-3 trial. Patients who fulfilled the eligibility crite-
ria for the CRASH-3 trial, with a GCS of 12 or less or intrac-
ranial bleeding on a CT scan done before randomisation, were 
eligible for inclusion in the IBMS. Routinely collected CT 
scans were manually examined on hospital software (Picture 
Archiving and Communication System) between February 
2016 and January 2019 across 14 hospitals in the UK and 
Malaysia. Most patients in the IBMS were randomised into 
the CRASH-3 trial within 3 h of injury (76%, n = 1350); the 
rest were randomised between 3 and 8 h of injury. Patients had 
a median age of 45 years (IQR 29–63), median systolic blood 
pressure of 136 mmHg (IQR 120–155), and median GCS of 7 
(IQR 3–10) (80% male, 20% female). In the CRASH-3 IBMS, 
a total of 65% of patients (n = 1147) had a baseline CT scan 
done within a median of 2 h after injury (IQR 1–2 h), of whom 
71% had another clinically indicated brain scan done within a 
median of 35 h after injury (IQR 19–77 h).
Simple validated scales were used to estimate intracranial 
haemorrhage volume on CT scans. The ABC/2 method is a 
quick and easy technique used to estimate intracranial haem-
orrhage volume. This method selects a representative slice 
near the centre of the haematoma on which the bleed is most 
visible. On this slice, two measurements are taken: (A) the 
maximal diameter; (B) width perpendicular to A. For the 
measurement of depth, the maximal number of slices on which 
the haematoma is visible is multiplied by slice thickness (C). 
These three measurements are multiplied and the sum divided 
by two (ABC/2) to provide the volume measurement in  cm3 
(ml). One cubic centimetre is equivalent to one millilitre. Intra-
parenchymal bleeding, epidural bleeding and intra-ventricular 
bleeding volumes were estimated using the ABC/2 method 
[5]. Because the ABC/2 method assumes haemorrhage has 
an almost spherical shape, an alternative method was used to 
estimate subdural bleeding volume, which is typically cres-
cent shaped. Subdural bleeding volume was estimated using 
its maximum diameter [5]. The occurrence of mass effect 
(sulcal effacement, ventricular effacement, midline shift) was 
also examined using scans and their accompanying radiology 
reports, which were rated at each hospital site by one outcome 
assessor. Anonymised scan ratings were entered into a web 
database developed for the purpose of the IBMS. All data were 
cleaned prior to analysis in statistical package Stata.
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Results
Intracranial bleeding on baseline CT scan
Figure 1 shows the type and frequency of intracranial bleed-
ing on baseline CT scans according to baseline GCS. A 
total of 61% of patients with a baseline scan presented with 
more than one type of bleed. With the exception of epidural 
bleeding, which was more prevalent in patients with mild 
to moderate GCS, all other bleed types were more com-
mon in patients with a severe GCS. Subdural bleeds had a 
larger median volume of 46 ml (IQR 27–71 ml) compared 
to epidural bleeds with 6 ml (IQR 2–20 ml), intra-parenchy-
mal bleeds with 1 ml (IQR 0.2–3 ml), and intra-ventricular 
bleeds with a median volume of 0·4 ml (IQR 0.1–2 ml).
Figure 2 shows the volume distribution of intracranial 
bleeding on baseline CT scans by pupil reactions and 
GCS. The median volumes of 64 ml (IQR 26–108 ml) in 
patients with no reactive pupils and 48 ml (IQR 3–93 ml) in 
patients with one reactive pupil were larger than 26 ml (IQR 
1–55 ml) in patients with two reactive pupils. The median 
volumes of 37 ml (IQR 3–75 ml) in patients with a severe 
GCS were greater than 28 ml (IQR 1–53 ml) for moderate 
GCS and 18 ml (IQR 0.2–41 ml) in mild GCS. But there is 
Fig. 1  Baseline prevalence and type of intracranial bleeding by Glasgow Coma Score (GCS)
Fig. 2  Baseline intracranial bleeding volume distribution
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substantial overlap in bleeding volumes between pupil reac-
tion groups and GCS groups.
We used data on the time of injury and time of CT scan to 
estimate the time-adjusted volume of intracranial bleeding. 
Table 1 shows the time-adjusted volume of bleeding by pupil 
reaction, GCS score, and type of bleed. The time-adjusted 
volume of bleeding was largest in those with un-reactive 
pupils and in those with severe GCS. Subdural bleeding 
was more rapid than epidural, intra-parenchymal, and intra-
ventricular bleeding.
But the bleeding rate may not be constant. We found a 
non-linear association between time and bleeding volume 
(see Fig. 3). The majority of expansion occurred in the first 
1–1.5 h after injury. Patients with a severe GCS seemed to 
bleed more and faster than patients with moderate to mild 
GCS.
Other intracranial pathologies on baseline CT scans
TBI patients often present with intracranial pathologies 
in addition to intracranial bleeding. Compared to patients 
with mild to moderate GCS, the prevalence of sulcal efface-
ment was greater in those with severe GCS (44% vs 59%; 
n = 190/433 vs n = 417/702), as was ventricular effacement 
(30% vs 47%; n = 128/433 vs 328/702), and midline shift 
(39% vs 48%; n = 169/433 vs. 337/702). Patients with a 
severe GCS and midline shift had a median shift of 7.4 mm 
(IQR 4.1–14.1 mm) whilst those with moderate to mild GCS 
had a median shift of 4.3 mm (IQR 2.8–7.1 mm).
Intracranial bleeding on follow‑up CT scans
Seventy-one percent (n = 812) of patients with a base-
line CT scan had a second or third clinically indicated 
CT scan. Over a third of these patients (n = 318) had a 
bleed on a subsequent scan that was not seen on the first 
scan. Patients who had their first CT scan soon after injury 
were more likely to have a new bleed on a subsequent 
scan. The prevalence of new bleeds among those scanne
d ≤ 1.5 h,  > 1.5–3 h,  > 3–8 h after injury was 46%, 38%, 
31%, respectively. For every 1 h increase from injury to 
the baseline scan, the risk of new bleeding on a further 
scan decreased by 12% (RR = 0·88 [95% CI 0.80–0.96], 
p = 0.0047) (adjusted for baseline GCS score, pupil reac-
tion, and time from injury to follow-up scan). The sooner 
the first scan was done after injury, the greater the oppor-
tunity for a new bleed to manifest on a further scan.
Baseline intracranial bleeding, raised intracranial 
pressure, un‑reactive pupils, and head injury death
An increase in the volume of intracranial bleeding (ml) 
was associated with an increase in the amount (mm) of 
midline shift (beta coefficient 0.10 [95% CI 0.09–0.10], 
p < 0.0001) (see Fig. 4). An increase in midline shift (mm) 
was associated with an increase in the risk of having one 
or more un-reactive pupils (RR 1.08 [95% CI 1.07–1.10], 
p < 0.0001) (see Fig.  5). Of those with baseline scans 
available for rating, 247 patients subsequently died from 
head injury. The median time-adjusted volume of intrac-
ranial bleeding among patients who died from head injury 
Table 1  Baseline intracranial bleeding volume (adjusted for time 
from injury to baseline scan)
a Glasgow Coma Scale (GCS) score assessed before intubation / seda-
tion (n = 814/1135) (72%)
Median (lower quartile, 
upper quartile) millilitres/
hour
All patients (n = 1135) 16 (1, 36)
Pupil reaction
None react (n = 141) 32 (14, 55)
One react (n = 94) 21 (2, 47)
Both react (n = 867) 13 (0.5, 31)
Glasgow coma scale (GCS) scorea
Severe (n = 388) 20 (2, 41)
Moderate (n = 331) 13 (0.3, 29)
Mild (n = 91) 8 (0.1, 20)
Bilateral un-reactive pupils or GCS  3a 
(n = 131)
28 (10, 54)
Type of intracranial bleeding
Subdural (n = 732) 25 (13, 42)
Epidural (n = 215) 4 (1, 10)
Intra-parenchymal (n = 709) 0.4 (0.1, 2)
Intra-ventricular (n = 184) 0.3 (0.1, 1)
Fig. 3  Association between time from injury to baseline scan and 
intracranial bleeding on baseline scan
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is 37 ml/h (IQR 18–58 ml/h) and in those who did not 
die of head injury is 11 ml/h (IQR 0.3–28 ml/h). Patients 
who died of head injury within 24 h of injury had a higher 
median time-adjusted bleeding volume of 51 ml/h (IQR 
28–73 ml/h), than those who died within 48–72 h of injury 
with 39 ml/h (IQR 19–56 ml/h), and beyond 72 h of injury 
with 28 ml/h (IQR 14–52 ml/h). 
Discussion
The CRASH-3 trial results suggest that the effect of 
tranexamic acid on head injury death depends on the time 
interval between injury and the start of treatment and on 
the severity of TBI [1]. Early treatment of patients with a 
mild to moderate GCS reduces head injury death, but there 
is no evidence for benefit in patients with a severe GCS, 
regardless of time to treatment. The CT scan data are con-
sistent with the hypothesis that tranexamic acid reduces head 
injury deaths by reducing intracranial bleeding. Patients with 
a mild to moderate GCS may be more likely to benefit from 
tranexamic acid because they have less intracranial bleeding 
at baseline. However, because bleeding occurs soon after 
injury, treatment delay reduces the benefit. On the other 
hand, patients with a severe GCS have less to gain from 
treatment because they already have extensive intracranial 
bleeding at baseline and/or other intracranial pathologies 
that are not affected by tranexamic acid. Our explanatory 
hypothesis is illustrated in Fig. 6. Please note that this is not 
a figure of the treatment effect seen in this study.
The CRASH-3 investigators anticipated in their statistical 
analysis plan [6] that TBI patients with GCS 3 or bilateral 
un-reactive pupils at baseline would have little potential 
to benefit from tranexamic acid and their inclusion in the 
Fig. 4  Association between baseline intracranial bleeding (ml) and 
baseline midline shift (mm)
Fig. 5  Association between midline shift and risk of un-reactive 
(compared to reactive) pupils at baseline
Fig. 6  Hypothesis: association 
between bleeding rate and treat-
ment effect
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analysis would dilute any treatment effect towards the null. 
They, therefore, pre-specified a sensitivity analysis that 
excluded these patients. Our CT data supports this decision, 
showing that these patients have extensive intracranial bleed-
ing, and other intracranial pathologies, prior to treatment. 
However, whilst patients with bilateral un-reactive pupils 
were excluded, those with unilateral un-reactive pupils were 
not, despite having high volumes of intracranial bleeding at 
baseline. Patients with unilateral un-reactive pupils might 
also have brain herniation and their inclusion might have 
diluted the treatment effect. Indeed, when patients with GCS 
3 and any un-reactive pupils at baseline are excluded, the 
effect of tranexamic acid on head injury death is noticeably 
larger [1].
Research in context
Evidence before this study
Although the risk of death and disability due to TBI may 
be reduced by preventing intracranial haemorrhage expan-
sion [7–9], there is limited evidence on bleeding expansion, 
particularly according to bleed type. One study of 142 TBI 
patients with a median GCS of eight suggested that intrac-
ranial haemorrhage expansion varies according to haemor-
rhage type [10]. Repeat CT scans done within 24 h of injury 
suggested that IPH appeared to expand in 51% of patients, 
EDH in 22%, SAH in 17% and SDH in 11% of patients. But 
this study considered any expansion between first and sec-
ond CT scans as evidence for expansion and did not measure 
the amount of expansion. The different eligibility criteria 
and definitions for expansion between studies make accurate 
estimation of expansion rates difficult. The decision for neu-
rosurgical haemorrhage evacuation between first and second 
scans also complicates assessment of expansion rates. Fur-
thermore, intracranial haemorrhage in its hyper-acute phase 
(before clotting) may not manifest on CT as its appearance 
is based on blood clot density changes over time [11–13]. 
Therefore, intracranial haemorrhage may have occurred by 
the point of the first CT scan, but not be visible. Studies that 
suggest that the prevalence of new bleeding on a second 
CT scan is greater when the first CT scan is done sooner 
after injury [7] may indicate that bleeding in its hyper-acute 
phase is not visible on a CT scan done very soon after injury 
[11–13], or that bleeding happens early. The absence of data 
on time from injury to scanning in many studies and the 
different times to scanning in studies that report these data 
limits understanding of the period over which expansion 
occurs or manifests on imaging.
The baseline CT data from the CRASH-3 IBMS improves 
understanding of the neuropathological presentation of TBI 
patients. The existing knowledge on intracranial haem-
orrhage, and other features of TBI, is based on smaller 
studies with different and restrictive inclusion criteria. The 
larger sample and less restrictive inclusion criteria of the 
CRASH-3 IBMS allowed this study to explore the natural 
occurrence of intracranial pathologies between injury and 
hospital admission. Since this is one of the largest descrip-
tive studies conducted in TBI, the results should be useful 
for emergency physicians, neurosurgeons, and other clinical 
specialties. Furthermore, this information can inform the 
design and interpretation of clinical trials including patients 
across TBI severity.
Added value of this study
The findings from the current study may help explain 
the results of the largest randomised trial in TBI to date; 
the recently published CRASH-3 trial. If at baseline TBI 
patients present with intracranial bleeding and a number of 
other neuropathological changes that TXA cannot plausi-
bly affect, their potential to benefit from TXA may reduce. 
Although clinical signs such as GCS score and pupil reaction 
were assessed at baseline, the CRASH-3 trial procedure did 
not involve examining the intracranial pathologies that may 
lead to these clinical signs. In severely injured patients, the 
immediate neurologic damage from the trauma may have 
been too severe to be alterable and TXA may have little 
potential to reduce intracranial bleeding progression and 
the risk of head injury death. In this study, we considered 
the occurrence of secondary neuropathological changes that 
occur after the primary TBI and before randomisation into 
the CRASH-3 trial. Knowledge of these changes can inform 
understanding of the potential for TXA to improve patient 
outcome and may help explain any variations in treatment 
effect by baseline injury severity in the CRASH-3 trial.
Implications of all the available evidence
The CRASH-3 trial treatment was given after arrival at 
hospital. Less than 20% of patients were treated within an 
hour of injury. Although there was no apparent benefit in 
patients with a low GCS on hospital arrival, if our explana-
tory hypothesis is correct, some of these patients might have 
benefited had they been treated in the pre-hospital setting. 
In many high-income countries, TXA is routinely adminis-
tered by paramedics at the scene of the injury to treat acute 
severe bleeding. In low- and middle-income settings, this is 
not always possible due to resource constraints and a lack of 
health workers who can administer intravenous drugs in the 
pre-hospital setting. Alternatives to intravenous administra-
tion of TXA such as intramuscular injection would be eas-
ier, require less training, and may reduce time to treatment. 
However, patients with more severe injuries in settings with 
insufficient in-hospital resources may die despite an early 
reduction in intracranial bleeding. Evidence suggests that 
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patients with severe TBI in low- and middle-income settings 
may be more likely to die compared to those in high-income 
settings. More rapid administration of TXA in settings with 
adequate medical care for patients with major trauma could 
increase the proportion of TBI patients who have the poten-
tial to benefit.
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a protocol and expect that a data access agreement is in place.
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vide consent and so consent was sought from the patient’s relative, legal 
representative, or the responsible clinician. If and when the patient 
regained capacity to provide informed consent, they were informed 
about the trial and written consent sought to continue participation in 
the trial. If a patient or patient representative declined consent, they 
were withdrawn from the trial. For patients who were included in the 
trial but did not regain capacity, written informed consent was sought 
from a relative or legal representative. The requirements of relevant 
local and national ethics committees were adhered to at all times. The 
CRASH-3 trial included consent to extract data from patient medical 
records. Collecting CT scan data for the explanatory study was consist-
ent with the consent procedure used in the CRASH-3 trial. It would be 
impractical to re-consent patients or relatives/legal representatives to 
access CT scans, particularly for patients who had deceased or were 
disabled as a result of their injuries where re-consent would have been 
distressing and unwelcome. The London School of Hygiene and Tropi-
cal Medicine and national Ethics Committees extended their approvals 
to extract CT data from the CRASH-3 trial without further patient 
consent. Patients who withdrew from the main CRASH-3 trial were 
not included in the explanatory study.
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